Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017 01 01; 2(1):79-85.

View in: PubMed

subject areas

Aged
Aminobutyrates
Biphenyl Compounds
Drug Combinations
Enalapril
Female
Heart Failure
Humans
Hyperkalemia
Incidence
Male
Middle Aged
Mineralocorticoid Receptor Antagonists
Practice Guidelines as Topic
Prospective Studies
Stroke Volume
Tetrazoles
Treatment Outcome
Valsartan

authors with profiles

Michael R. Zile